NewsBenzingaMyers Indus Q3 EPS rettificato di $0,32 non raggiunge la stima di $0,45, vendite per $171,340 milioni superano la stima di $163,800 milioni Myers Indus Q3 EPS rettificato di $0,32 non raggiunge la stima di $0,45, vendite per $171,340 milioni superano la stima di $163,800 milioni Benzinga 2026.10.29 11:06 (GMT+0) Open on Benzinga Other news Karyopharm Therapeutic Common Shares To Be Suspended, Effective Nov. 11; To Trade On OTC Under KPTIQ Ticker Cantor Fitzgerald Maintains Overweight on Hut 8, Lowers Price Target to $127 Why Is Joby Aviation Stock Surging Thursday? HubSpot Analysts Slash Their Forecasts After Q3 Results Wall Street's Most Accurate Analysts Spotlight On 3 Energy Stocks Delivering High-Dividend Yields Global Payments Lowers FY2026 GAAP EPS Guidance from $(3.85)-$(3.77) to $(3.90)-$(3.81) vs $(2.94) Est; Lowers FY2026 Sales Guidance from $13.100B-$13.177B to $12.946-$13.023
Karyopharm Therapeutic Common Shares To Be Suspended, Effective Nov. 11; To Trade On OTC Under KPTIQ Ticker
Global Payments Lowers FY2026 GAAP EPS Guidance from $(3.85)-$(3.77) to $(3.90)-$(3.81) vs $(2.94) Est; Lowers FY2026 Sales Guidance from $13.100B-$13.177B to $12.946-$13.023
